CANCER RESEARCH
TABLE OF CONTENTS

IN THE SPOTLIGHT

PRIORITY REPORT

CANCER BIOLOGY

CANCER METABOLISM AND MOLECULAR MECHANISMS

TABLE OF CONTENTS

TABLE OF CONTENTS

ABOUT THE COVER



Defects in DNA repair pathways play a pivotal role in tumor development and response to therapy. USP1 is a critical dependency in tumors with homologous recombination (HR) repair deficiency. The cover image illustrates a CryoEM structure of the newly developed USP1 inhibitor, KSQ-4279, binding to the USP1/UAF1 deubiquitinase complex. Treatment with KSQ-4279 is an effective strategy for inducing regression of HR-deficient tumors and overcoming PARP inhibitor resistance. For details, see article by Cadzow and colleagues on page 3419.

doi: 10.1158/0008-5472.CAN-84-20-CVR

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.